New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer Life Science Investing
BioVaxys Reports Positive Phase 2 Data for Maveropepimut + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer Life Science Investing
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option Life Science Investing
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy Life Science Investing
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Life Science Investing
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Life Science Investing
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Life Science Investing
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting Life Science Investing
AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Life Science Investing
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update Life Science Investing